CRNO B Stock Overview
Cereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Cereno Scientific AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 5.70 |
52 Week High | SEK 9.50 |
52 Week Low | SEK 2.50 |
Beta | 0.16 |
11 Month Change | 0% |
3 Month Change | -9.16% |
1 Year Change | 16.45% |
33 Year Change | 31.03% |
5 Year Change | 57.46% |
Change since IPO | -8.80% |
Recent News & Updates
Shareholder Returns
CRNO B | SE Biotechs | SE Market | |
---|---|---|---|
7D | -8.5% | 2.1% | 0.3% |
1Y | 16.4% | 34.0% | 25.7% |
Return vs Industry: CRNO B underperformed the Swedish Biotechs industry which returned 29.1% over the past year.
Return vs Market: CRNO B underperformed the Swedish Market which returned 24.6% over the past year.
Price Volatility
CRNO B volatility | |
---|---|
CRNO B Average Weekly Movement | 11.9% |
Biotechs Industry Average Movement | 9.3% |
Market Average Movement | 5.4% |
10% most volatile stocks in SE Market | 11.3% |
10% least volatile stocks in SE Market | 3.1% |
Stable Share Price: CRNO B's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: CRNO B's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 5 | Sten Sorensen | www.cerenoscientific.com |
Cereno Scientific AB (publ), clinical stage biotechnology company, develops therapeutics to treat cardiovascular and rare diseases worldwide. The company’s lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and antithrombotic properties. Its preclinical drug candidates comprise CS585 and CS014 that is in pre clinical stage for the treatment of cardiovascular diseases.
Cereno Scientific AB (publ) Fundamentals Summary
CRNO B fundamental statistics | |
---|---|
Market cap | SEK 1.61b |
Earnings (TTM) | -SEK 69.48m |
Revenue (TTM) | SEK 68.72m |
23.4x
P/S Ratio-23.1x
P/E RatioIs CRNO B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CRNO B income statement (TTM) | |
---|---|
Revenue | SEK 68.72m |
Cost of Revenue | SEK 0 |
Gross Profit | SEK 68.72m |
Other Expenses | SEK 138.20m |
Earnings | -SEK 69.48m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 21, 2024
Earnings per share (EPS) | -0.25 |
Gross Margin | 100.00% |
Net Profit Margin | -101.10% |
Debt/Equity Ratio | 17.9% |
How did CRNO B perform over the long term?
See historical performance and comparison